GEN Exclusives

More »

GEN News Highlights

More »
Aug 14, 2008

JHU to Use Axela’s Assay to Evaluate a Prognostic Marker for Acute Myocardial Infarction

  • Johns Hopkins University School of Medicine inked a deal to use Axela’s dotLab® technology in a clinical trial evaluating circulating cardiac Troponin complexes (cTn) in patient samples.

    The study is trying to assess the prognostic value of Troponin complexes as well as post-translational modifications to cardiac Troponin I (cTnI) in patients with acute myocardial infarction (AMI).

    Troponin is a complex of three proteins (cTnI, cTnC, and cTnT) that is integral to the contraction of cardiac muscle. It is released into the blood upon cardiac muscle necrosis and cell death.
    The dotLab assay can detect circulating cTnI bound to cTnC and cTnT in the serum of patients with AMI. It is also able to probe the integrity of cTnI and determine if the protein is degraded by looking for the presence of specific epitopes.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »